Document Type

Journal Article

Publication Title

Heliyon

Volume

10

Issue

4

Publisher

Elsevier

School

School of Medical and Health Sciences / Centre for Precision Health

RAS ID

65506

Funders

Xuzhou Medical University Outstanding Talents Research Start-up Fund / Provincial Funding Projects for Basic Science (Natural Science) Research in Higher Education Institutions in Jiangsu Province / Research Foundation for Advanced Talents of Guangdong Provincial People’s Hospital

Comments

Zhang, M., Wu, Y., Mou, J., Yao, Y., Wen, P., Liu, X., . . . Wang, L. (2024). The global landscape of immune-derived lncRNA signature in colorectal cancer. Heliyon, 10(4), article e25568. https://doi.org/10.1016/j.heliyon.2024.e25568

Abstract

Background: Colorectal cancer (CRC) is a highly heterogeneous cancer. This heterogeneity has an impact on the efficacy of immunotherapy. Long noncoding RNAs (lncRNAs) have been found to play regulatory functions in cancer immunity. However, the global landscape of immune-derived lncRNA signatures has not yet been explored in colorectal cancer. Methods: In this study, we applied DESeq2 to identify differentially expressed lncRNAs in colon cancer. Next, we performed an integrative analysis to globally identify immune-driven lncRNA markers in CRC, including immune-associated pathways, tumor immunogenomic features, tumor-infiltrating immune cells, immune checkpoints, microsatellite instability (MSI) and tumor mutation burden (TMB). Results: We also identified dysregulated lncRNAs, such as LINC01354 and LINC02257, and their clinical relevance in CRC. Our findings revealed that the differentially expressed lncRNAs were closely associated with immune pathways. In addition, we found that RP11-354P11.3 and RP11-545G3.1 had the highest association with the immunogenomic signature. As a result, these signatures could serve as markers to assess immunogenomic activity in CRC. Among the immune cells, resting mast cells and M0 macrophages had the highest association with lncRNAs in CRC. The AC006129.2 gene was significantly associated with several immune checkpoints, for example, programmed cell death protein 1 (PD-1) and B and T lymphocyte attenuator (BTLA). Therefore, the AC006129.2 gene could be targeted to regulate the condition of immune cells or immune checkpoints to enhance the efficacy of immunotherapy in CRC patients. Finally, we identified 15 immune-related lncRNA-generated open reading frames (ORFs) corresponding to 15 cancer immune epitopes. Conclusion: In conclusion, we provided a genome-wide immune-driven lncRNA signature for CRC that might provide new insights into clinical applications and immunotherapy.

DOI

10.1016/j.heliyon.2024.e25568

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Included in

Diseases Commons

Share

 
COinS